Key result
Plasma homocysteine shows no association with left-sided valvular heart disease severity or cardiac function in horses.
Why the study?
Homocysteine is a cardiovascular biomarker in humans with established equine reference ranges, but its assay stability characteristics and associations with echocardiographic variables in horses with left-sided valvular regurgitation required investigation.
Observational (n=169)
Yes
Plasma homocysteine concentration is not associated with echocardiographic changes in left-sided valvular heart disease in horses, limiting its utility as a cardiac biomarker in this species.
No role for homocysteine as biomarker in equine left-sided valvular disease; leaves open its utility in other species or conditions.
In human medicine, homocysteine, a sulfur-containing amino acid, is used as a biomarker reflecting endothelial dysfunction, inflammation, thrombogenesis, oxidative stress and cardiovascular disease. An automated enzyme-cycling assay for homocysteine, established for humans, has been validated and reference ranges have been created for horses. In this study the homocysteine assay was further evaluated by assessing short-term stability (whole blood and plasma samples stored at 4 °C and room temperature for 24 h), long-term stability (two years), the effect of different anticoagulants (lithium heparin, sodium citrate, EDTA, no additives) and repeated freeze–thaw cycles (five times). Further, associations between plasma homocysteine concentrations ([HCY]p) and echocardiographic variables of left heart size, left heart function, and left-sided valve regurgitation were investigated. Homocysteine concentrations remained stable in whole blood at room temperature for at least four hours, or longer when plasma is separated and kept at 4 °C. Samples could be collected in serum blood tubes, lithium heparin (LH), or EDTA without affecting homocysteine concentrations ([HCY]). Plasma [HCY] in frozen samples increased slightly with storage time (years), though up to five freeze–thaw cycles did not affect [HCY]p. In a cohort of 169 horses with left-sided valvular regurgitation, plasma creatinine concentrations and age were positively associated with higher [HCY]p, but no association between [HCY]p and changes in cardiac size, function or severity of valvular regurgitation could be established. Homocysteine is not associated with left-sided valvular heart disease in horses and is not a useful biomarker for structural or functional cardiac changes.
No takes yet. Share an insight, caveat, or question.
Egli et al. (2026) conducted an observational in Left-sided valvular heart disease (n=169). Plasma homocysteine concentration was evaluated on Association between plasma homocysteine concentrations and echocardiographic variables of left heart size, function, and regurgitation severity. Plasma homocysteine concentration is not associated with left-sided valvular heart disease severity, cardiac size, or function in horses, limiting its utility as a cardiac biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: